FOXO4-DRI

FOXO4-DRI is a D-retro-inverso peptide derived from a segment of the Forkhead box O4 (FOXO4) transcription factor: all-D amino acids in reversed sequence, a topology that preserves side-chain presentation while conferring near-complete resistance to proteolysis. Where a standard peptide is degraded within minutes, FOXO4-DRI remains stable for 72 hours or more after administration, which underpins its every-other-day rather than daily schedule.

It was developed by Peter de Keizer and colleagues at Erasmus University Medical Center. Baar et al. (2017), Cell, established the mechanism and demonstrated in vivo efficacy in both accelerated-ageing XpdTTD/TTD and naturally aged mice, with restoration of fur density, exploratory behaviour, running wheel activity, and renal and hepatic function markers. Selectivity for senescent over healthy cells was 11.73 fold.

The compound is classed as a senolytic alongside dasatinib plus quercetin and BCL-2 inhibitors such as ABT-263, but acts via a distinct axis: competitive disruption of the FOXO4–p53 interaction rather than inhibition of tyrosine kinase or BCL-2 family pro-survival signalling.

Nomenclature: vendor sheets sometimes render the name "FOX04-DRI" with a numeral zero; the gene and protein are FOXO4, and that spelling is used here with the variant retained as an alias.

Regulatory and evidentiary status: no completed human clinical trials; Cleara Biotech, formed to commercialise the academic work, remained preclinical as of 2025. The full in vivo findings of Baar et al. have not been independently replicated. All human protocols are extrapolations from 5 mg/kg intraperitoneal mouse dosing and self-experimentation, and are deliberately conservative given the compound's interaction with p53.

Supplied as a 10 mg lyophilised vial for subcutaneous administration.

Cellular senescence is a damage response in which cells with excessive genotoxic, oxidative, or replicative stress undergo permanent cell-cycle arrest as a tumour-suppressive safeguard, but fail to complete apoptosis. The resulting cells persist and adopt the Senescence-Associated Secretory Phenotype (SASP), releasing pro-inflammatory cytokines that damage adjacent tissue and drive the chronic low-grade inflammation of ageing. SASP cytokines also induce macrophages to upregulate CD38, an NAD+-consuming enzyme, linking senescent cell burden to age-related NAD+ decline.

Survival of senescent cells depends on a FOXO4-mediated block on p53. Endogenous FOXO4 is upregulated in senescent cells and binds p53, sequestering it in the nucleus and preventing its translocation to the mitochondria and initiation of intrinsic apoptosis.

FOXO4-DRI is a cell-permeable competitor for the same p53 binding site. On entry it displaces endogenous FOXO4, releasing p53 from nuclear sequestration; p53 then relocates to the mitochondria and triggers the apoptotic cascade. Bourgeois et al. (2025), Nature Communications, resolved the interaction structurally: the disordered FOXO4-DRI peptide binds the disordered p53 transactivation domain 2 (p53TAD2), forming a transiently folded complex. Both the FOXO4-derived region and the cationic cell-penetrating segment contribute to affinity, and p53 phosphorylation increases affinity for both FOXO4 and FOXO4-DRI, so binding is biased toward cells in which p53 is already activated.

Selectivity follows from the mechanism. Non-senescent cells do not express elevated FOXO4 and are not p53-sequestered, so there is nothing for the peptide to displace. Baar et al. (2017) reported 11.73 fold preference for senescent over healthy cells — highly preferential but not exclusive.

The DRI topology confers stability of 72 hours or more, so a single dose maintains disruption of the FOXO4–p53 interaction across an every-other-day interval. Clearance is a discrete event rather than a maintained state, which is the rationale for short cycles and long rest periods rather than continuous exposure.

Preclinical only; no human efficacy data exist.

Baar et al. (2017), Cell: in XpdTTD/TTD accelerated-ageing and naturally aged mice, 5 mg/kg intraperitoneal every other day for three doses reduced senescent cell markers across multiple organ systems, restored fur density, exploratory behaviour, and responsiveness to stimuli, significantly increased voluntary running wheel activity (XpdTTD/TTD mice rose from 1.37 km/day toward wild-type levels), and improved serum creatinine, plasma urea, and hepatic function markers. The peptide also neutralised doxorubicin chemotoxicity by clearing therapy-induced senescent cells.

Zhang et al. (2020), Aging: naturally aged mice (20 to 24 months) at the same regimen showed significantly increased serum testosterone 30 days post-treatment, reduced testicular p53, p21, and p16, and increased CYP11A1, with no change in body or testis weight — consistent with selective clearance of senescent Leydig cells rather than systemic endocrine disruption.

Xu et al. (2021), Frontiers in Bioengineering and Biotechnology: in expanded human chondrocytes in vitro, senescent cells at population doubling level 9 were significantly reduced with decreases in SA-beta-gal, p53, p16, and p21, while non-senescent cells at population doubling level 3 showed no noticeable loss.

Hu et al. (2025), Frontiers in Bioengineering and Biotechnology: 5 mg/kg in naturally aged and D-galactose-induced ageing mice reduced aortic wall thickness, lowered pulse wave velocity, and decreased p21 and p16; in senescent endothelial cells it restored tube formation and migration and reduced reactive oxygen species.

A 2025 Communications Biology study demonstrated apoptosis of keloid senescent fibroblasts via nuclear exclusion of p53 phosphorylated at serine 15.

Downstream, reduced SASP output is expected to lower CD38 induction in macrophages and thereby relieve one driver of NAD+ decline, per Covarrubias et al. (2020).

In practice, reported subjective effects are subtle: gradual improvements in energy, joint comfort, skin texture, and recovery; a substantial fraction of users report no discernible change.

No human outcome data exist; expectations derive from animal timelines and user reports.

FOXO4-DRI is administered in discrete short cycles rather than continuously. The DRI-conferred stability of 72 hours or more supports every-other-day dosing, and the intended outcome — a bolus reduction in senescent cell burden followed by tissue regeneration — does not require ongoing exposure.

During treatment, transient fatigue is the most commonly reported effect, with some users describing mild flu-like symptoms and temporary muscle soreness during the clearance phase, consistent with immune processing of apoptotic cells. Injection site erythema and mild irritation are common.

After treatment, effects are gradual and subtle. Users report modest improvements in energy, joint comfort, skin texture, and recovery capacity over subsequent weeks; a substantial proportion report minimal subjective change despite adherence to standard protocols, which is not in itself evidence of inactivity given that clearance is a cellular event. A single notable self-experimenter reported resolution of chronic back pain, 90% reduction in cervical spine pain, cessation of twice-weekly headaches, and approximately 90% resolution of 15-year wrist and forearm RSI pain; this is anecdotal and uncorroborated.

The user base is small relative to common peptides owing to cost and the experimental status of the compound, so the anecdotal record is thin. No readily available clinical assay quantifies senescent cell burden, so treatment response cannot be measured directly; the long rest intervals between cycles are intended partly to allow assessment of response before repeating.

Expectations should be calibrated against foundations: sleep, nutrition, and exercise account for far more of age-related fatigue than senescent cell burden. FOXO4-DRI is positioned as an adjunct to an established foundation rather than a substitute for one.

Human dosing is not established by clinical trials. Protocols are extrapolations from murine data and self-experimentation, and are conservative by design because the target is p53, a critical tumour suppressor, and aggressive dosing raises theoretical off-target concerns.

Dose context. Baar et al. (2017) and subsequent studies used 5 mg/kg intraperitoneally every other day for three total doses. Linear translation to a 60 kg human would give approximately 300 mg per dose; this is not used because peptide dosing does not scale linearly across species, intraperitoneal administration is impractical for self-administration, and the DRI modification alters pharmacokinetics. Practical protocols are subcutaneous and roughly two orders of magnitude lower.

Reconstitution. 10 mg vial in 1 mL bacteriostatic water: 10 mg/mL, 100 mcg per unit on a U-100 insulin syringe. 5 mg = 50 units; 3 mg = 30 units.

Standard protocol. 3 to 5 mg subcutaneous every other day, 3 doses total, repeated 1 to 3 times per year. Tiers in practice: conservative 2 to 3 mg, standard 3 to 5 mg, aggressive 5 to 10 mg, each every other day for 3 doses. A 3-dose cycle consumes 0.9 to 1.5 mg per cycle at the standard tier — i.e. one 10 mg vial covers a cycle at any tier up to the aggressive ceiling of 30 mg total, which would require three vials.

Alternative protocol. 0.3 to 0.5 mg daily for 7 days, repeated every other week. Rationale: sustained low-level disruption of the FOXO4–p53 interaction. Less precedent than the standard cycling approach.

Cycle rationale. Senescent cell clearance is a discrete event; continuous exposure is unnecessary. Rest intervals allow replacement of cleared cells with healthy tissue, reduce theoretical risk from chronic p53 modulation, and permit assessment of response before repeating. Repeating 1 to 3 times per year addresses newly accumulated senescent cells.

Legacy schedule. An earlier vendor sheet specified 3 mL reconstitution and continuous daily dosing at 250 mcg (weeks 1–4), 375 mcg (weeks 5–8), and 500 mcg (weeks 9–16) on an 8–16 week cycle with a 4–8 week washout; its printed draws (8, 11, 15 units) implied a 10 mg vial. Total exposure over 16 weeks was 45.5 mg. That regimen runs contrary to the intermittent-clearance rationale and is retained for reference only.

Timing. Any time of day; no fasting requirement; no timing constraints relative to meals or other compounds. No special storage or handling requirements.

Preclinical evidence is substantial; human clinical evidence is absent. Cleara Biotech, formed to commercialise the work, remains preclinical as of 2025.

Baar et al. (2017), Cell. Established the mechanism: FOXO4-DRI competes with endogenous FOXO4 for p53, releasing p53 from nuclear sequestration to trigger mitochondrial apoptosis. Selectivity 11.73-fold for senescent over healthy cells. In XpdTTD/TTD accelerated-ageing mice and naturally aged mice, 5 mg/kg intraperitoneally every other day for three doses restored fur density and exploratory behaviour, increased running wheel activity (XpdTTD/TTD from 1.37 km/day towards normal), and improved serum creatinine, plasma urea, and liver markers. It also neutralised doxorubicin chemotoxicity. Single group; no independent replication of the full in vivo findings.

Zhang et al. (2020), Aging. Naturally aged mice (20 to 24 months), same regimen. At 30 days: significantly increased serum testosterone, reduced p53, p21, and p16 in testicular tissue, increased CYP11A1, no change in body or testis weight, consistent with selective Leydig cell senolysis.

Xu et al. (2021), Frontiers in Bioengineering and Biotechnology. In vitro expanded human chondrocytes: senescent cells at population doubling level 9 were significantly reduced with decreased SA-beta-gal, p53, p16, p21; non-senescent cells at population doubling level 3 showed no noticeable loss.

Bourgeois et al. (2025), Nature Communications. Structural mapping: FOXO4-DRI binds the disordered p53 transactivation domain 2 (p53TAD2) forming a transiently folded complex; both the FOXO4-derived region and the cationic cell-permeability segment contribute; p53 phosphorylation enhances affinity, rationalising selectivity.

Hu et al. (2025), Frontiers in Bioengineering and Biotechnology. 5 mg/kg in naturally aged and D-galactose models reduced aortic wall thickness, lowered pulse wave velocity, decreased p21 and p16; restored tube formation and migration in senescent endothelial cells with reduced ROS.

Communications Biology (2025). Apoptosis of keloid senescent fibroblasts via nuclear exclusion of p53 phosphorylated at serine 15.

Covarrubias et al. (2020) links SASP cytokines to CD38 upregulation in macrophages and NAD+ decline, the basis for the proposed downstream NAD+ benefit.

Tolerability across animal studies is good; no serious adverse effects documented. No human safety data.